Dr. Svensson on the Impact of PD-L1 Status in Gastric and Esophageal Adenocarcinoma

Video

Maria Svensson, MD, Lund University, discusses the impact of determining PD-1 and PD-L1 status for patients with esophageal and gastric adenocarcinoma.

Maria Svensson, MD, Lund University, discusses the impact of determining PD-L1 status for patients with esophageal and gastric adenocarcinoma.

In a study of patients with resectable esophageal and gastric cancer, investigators sought to examine the expression of PD-L1 in tumor cells and tumor-infiltrating immune cells, and the PD-1 receptor as it relates to mismatch repair (MMR) status.

It is important to find good biomarkers for prognosis, explains Svensson. Patients with high PD-L1 expression in tumor-infiltrating lymphocytes (TILs) had prolonged survival. In this study, the prognostic value was evident in MMR-proficient tumors. PD-L1 expression and MMR status can be useful in the clinic in the future for different settings, adds Svensson.

Related Videos
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Julia Foldi, MD, PhD
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Abdulrahman Sinno, MD
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Erin K. Crane, MD, MPH
Omid Hamid, MD